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Fatty acid binding protein
Kidney disease
A B S T R A C T
The X-linked inherited muscle wasting disease Duchenne muscular dystrophy, which is caused by primary ab-
normalities in the membrane cytoskeletal protein dystrophin, is a multi-system disorder. Highly progressive
forms of dystrophinopathy are associated with a complex secondary pathophysiology, including renal dys-
function. It was therefore of interest to carry out a systematic survey of potential proteome-wide changes in the
kidney of the established mdx-4cv mouse model of dystrophinopathy. Of 5878 mass spectrometrically identified
kidney proteins, 82 versus 142 proteins were shown to be decreased or increased, respectively, in association
with muscular dystrophy. The most decreased versus increased protein species are the ACSM3 isoform of mi-
tochondrial acyl-coenzyme A synthetase and the FABP1 isoform of fatty acid binding protein, respectively. Both
proteomic findings were verified by immunofluorescence microscopy and immunoblot analysis. Interestingly,
haematoxylin/eosin staining indicated diffuse whitish deposits in the mdx-4cv kidney, and an increased intensity
of Sudan Black labelling of kidney cells revealed ectopic fat deposition. Although the proteomic results and cell
biological findings do not demonstrate a direct functional link between increased FABP1 and fat accumulation,
the results suggest that the up-regulation of FABP1 may be related to abnormal fat metabolism. This makes
FABP1 potentially a novel pathobiochemical indicator for studying kidney abnormalities in the mdx-4cvmodel of
dystrophinopathy.
1. Introduction
Paediatric neuromuscular disorders include a variety of mostly in-
herited diseases of the peripheral nervous system and the skeletal
musculature, including several types of muscular dystrophy (Dowling
et al., 2018). X-linked Duchenne muscular dystrophy is characterized
by primary abnormalities in the DMD gene (Koenig et al., 1987;
Guiraud et al., 2015), which encodes the membrane cytoskeletal pro-
tein dystrophin that belongs to the spectrin-like superfamily of actin-
crosslinking proteins (Koenig et al., 1988; Delalande et al., 2017). A
range of genetic mutations results in the almost complete loss of the
full-length Dp427-M isoform of dystrophin (Bladen et al., 2015). The
concomitant drastic reduction of the sarcolemmal dystrophin-asso-
ciated glycoprotein complex causes loss of protein function and is as-
sociated with progressive skeletal muscle wasting (Ervasti et al., 1990;
Ohlendieck et al., 1993; Murphy and Ohlendieck, 2015). Besides fibre
degeneration, key features of muscular dystrophy are disturbed ion
homeostasis, abnormal energy metabolism, reactive myofibrosis and
adaptive immune responses to chronic muscle damage (Allen et al.,
2016; Holland et al., 2016; Tidball et al., 2018; Lindsay et al., 2019). In
addition to neuromuscular symptoms, dystrophinopathies are char-
acterized by a multi-system pathology that features respiratory dys-
function, heart failure, scoliosis, metabolic disturbances and cognitive
impairments (Goemans and Buyse, 2014; Latimer et al., 2017; Cordova
et al., 2018), as well as renal and urinary tract manifestations (Askeland
et al., 2013; Bertrand et al., 2016; Braat et al., 2015).
Although cardio-respiratory failure is the main cause of death in
Duchenne patients (Moriuchi et al., 1991), the systematic application of
cardio-protective drug therapy, including beta-blockers, angiotensin-
converting enzyme inhibitors and diuretics to treat cardiac insufficiency
(Hor et al., 2018) and mechanical ventilator support to counter-act
contractile weakness of respiratory muscles (LoMauro et al., 2015) has
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drastically enhanced the prognosis in dystrophinopathy (Messina and
Vita, 2018). However, improved life expectancy is associated with an
altered rate of circulation due to an extended period of decreased car-
diac output and this in turn causes progressive dysfunction in other
organ systems. As a serious complication in advanced stages of X-linked
muscular dystrophy, contractile weakness was shown to be associated
with the cardio-renal syndrome (Villa et al., 2016) and fatal cases of
acute renal failure have been described (Matsumura et al., 2012). Non-
ambulatory Duchenne patients have an increased risk of symptomatic
nephrolithiasis (Shumyatcher et al., 2008; Singh et al., 2007) and re-
duced kidney perfusion (Motoki et al., 2015), whereby renal dysfunc-
tion can be identified and monitored by the Cystatin C-estimated glo-
merular filtration rate (Villa et al., 2016; Viollet et al., 2009).
Because of these renal abnormalities in dystrophic patients, it was of
interest to evaluate potential proteome-wide changes in the kidney in
association with dystrophinopathy. However, due to the extremely re-
stricted amounts of patient tissue biopsy material available to study
genetic diseases of childhood, animal models have been widely em-
ployed to study the molecular pathogenesis of X-linked muscular dys-
trophy (McGreevy et al., 2015; Rodrigues et al., 2016; Wilson et al.,
2017). In analogy, we have used here kidney specimens from the es-
tablished mdx-4cv mouse model of X-linked muscular dystrophy (Banks
et al., 2010; Im et al., 1996; Tichy and Mourkioti, 2017). Genetic mdx-
type mouse models have previously been used for studying cellular
abnormalities in the kidney (Gusel’nikova et al., 2018) and the eva-
luation of kidney toxicity in relation to pharmacological applications
(Reay et al., 2015) and experimental exon-skipping therapy (Zhang
et al., 2015) to treat muscular dystrophy. Importantly, adult mdx mice
were shown to exhibit reduced renal function using serum Cystatin C
testing and dynamic computed tomography scanning with an angio-
graphic agent (Wada et al., 2019). These renal functional tests have
demonstrated the usefulness of mdx-type models for screening the
kidney from dystrophin-deficient animals. In this report, the systematic
proteomic survey of the mdx-4cv kidney has revealed the drastic ele-
vation of the FABP1 isoform of fatty acid binding protein (Hotamisligil
and Bernlohr, 2015), which may be related to ectopic fat deposition and
renal dysfunction (Xu et al., 2015).
2. Materials and methods
2.1. Materials
General materials and analytical grade reagents were purchased
from Sigma Chemical Company (Dorset, UK), Bio-Rad Laboratories
(Hemel-Hempstead, Hertfordshire, UK) and GE Healthcare (Little
Chalfont, Buckinghamshire, UK). Sequencing grade-modified trypsin,
Lys-C and Protease Max Surfactant Trypsin Enhancer were obtained
from Promega (Madison, WI, USA). Whatman nitrocellulose transfer
membranes and Invitrogen NuPAGE Novex Bis‐Tris gels were from Bio-
Science Ltd (Dun Laoghaire, Ireland). InstantBlue Coomassie Protein
Stain was purchased from Expedeon (Heidelberg, Germany). The che-
miluminescence substrate and protease inhibitors were obtained from
Roche Diagnostics (Mannheim, Germany). Primary antibodies were
from Cell Signaling Technology, Leiden, Netherlands (rabbit mAb13368
to fatty acid binding protein FABP1), Proteintech, Manchester, UK
(rabbit pAb 10168-2-AP to the ACSM3 isoform of mitochondrial acyl-
coenzyme A synthetase), R&D Systems, Abingdon, UK (mouse mAb
MAB5718 to glyceraldehyde-3-phosphate dehydrogenase) and Leica
Biosystems, Wetzlar, Germany (mouse mAb NCL-DYS1/clone-Dy8/6C5
to dystrophin). Anti-rabbit and anti-mouse peroxidase conjugated sec-
ondary antibodies were from Cell Signaling Technology. For immuno-
fluorescence microscopy, normal goat serum, goat anti-mouse IgG RRX
(Rhodamine Red-X) and anti-rabbit Alexa Fluor 488 antibody were
purchased from Molecular Probes, Life Technologies (Darmstadt,
Germany) and Jackson ImmunoResearch (West Grove, PA, USA), re-
spectively. The embedding medium Fluoromount G was from Southern
Biotech (Birmingham, AL, USA).
Fig. 1. Cell biological characterization of the
mdx-4cv mouse model of dystrophinopathy.
Shown are transverse cryosections of wild type
(wt) versus dystrophic mdx-4cv gastrocnemius
muscle stained with haematoxylin and eosin (H
&E) and labelled with antibodies to the full-
length Dp427 isoform of dystrophin. The dys-
trophic specimens clearly exhibit the almost
complete loss of dystrophin at the sarcolemma,
as well as central nucleation, cellular degen-
eration, inflammation and abnormal fibre dia-
meters. Bar equals 50 μm.
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2.2. Preparation of kidney samples from the mdx-4cv mouse model of
dystrophinopathy
For the comparative mass spectrometric profiling of the kidney
proteome from dystrophic mice, whole kidney samples from 12-month
old mdx-4cv mice versus age-matched control C57/BL6 mice were ob-
tained from the Bioresource Unit of the University of Bonn (Murphy
et al., 2018a). Mice were kept under standard conditions and all pro-
cedures adhered to German legislation on the use of animals in ex-
perimental research. The mdx-4cv mouse model of Duchenne muscular
dystrophy is one of four chemical variants of the spontaneous mdx
mouse (Partridge, 2013), which has been generated on the C57/BL6
background by chemical mutagenesis (Chapman et al., 1989; Danko
et al., 1992; Shin et al., 2011). Mice were sacrificed by cervical dis-
location and kidneys were dissected and quick-frozen in liquid nitrogen.
Tissue specimens were transported to Maynooth University in ac-
cordance with the Department of Agriculture (animal by-product reg-
ister number 2016/16 to the Department of Biology, National Uni-
versity of Ireland, Maynooth) on dry ice and stored at −80 °C prior to
analysis.
For sample preparation, 25mg of kidney tissue was lysed by
homogenisation with 200 μl of lysis solution (4 % SDS, 100mM Tris-Cl
pH7.6, 0.1 M DTT) and incubated at 95 °C for 3min and then sonicated
for 30 s. The lysate was clarified by centrifugation at 16,000xg for
5min. 10 μl of lysate was mixed with 200 μl of 8M urea, 0.1M Tris
pH8.9 in filter units (Sartorius, Vivacon 500, Product number:
VN0H22) and centrifuged at 14,000xg for 15min. Samples were sub-
sequently processed according to the standardized FASP protocol for
filter-aided sample preparation (Wiśniewski et al., 2009).
2.3. Label-free liquid chromatography mass spectrometry
Reverse-phased capillary high pressure liquid chromatography was
carried out using the UltiMate 3000 nano system (Thermo Scientific)
coupled directly in-line with the Thermo Orbitrap Fusion Tribrid Mass
Spectrometer (Thermo Scientific) (Murphy et al., 2019b). The digested
kidney protein samples (1 μl ∼ 800 ng peptide) were loaded onto the
trapping column (PepMap100, C18, 300 μm ×5mm) at a flow rate of
25 μl/min with 2 % (v/v) acetonitrile (ACN), 0.1 % (v/v) trifluoroacetic
acid (TFA) for 3min before being resolved onto an analytical column
(Acclaim PepMap 100, 75 μm ×50 cm, 3 μm bead diameter column).
Peptides were eluted using the following binary gradient; solvent A (0.1
% (v/v) formic acid in LC–MS grade water) and 2–27.5 % solvent B (80
% (v/v) ACN, 0.08 % (v/v) formic acid in LC–MS grade water) for
110min at a flow rate of 300 nl/min. For peptide ionization, a voltage
of 1.9 kV was applied and a capillary temperature of 320 °C was used.
Data-dependent acquisition with full scans in the 375–1500m/z range
was performed using an Orbitrap mass analyser with a resolution of
120,000 (at m/z 200), a targeted automatic gain control (AGC) value of
4E+05 and a maximum injection time of 50ms. The number of se-
lected precursor ions for fragmentation was determined by the top-
speed acquisition algorithm. Selected precursor ions were isolated in
the Quadrupole with an isolation width of 1.6 Da. Peptides with a
charge state of 2+ to 6+ were analysed and a dynamic exclusion was
applied after 60 s. Precursor ions were fragmented using higher energy
collision-induced dissociation (HCD) with a normalized collision energy
Fig. 2. Overview of the comparative proteomic profiling of the kidney from the mdx-4cv model of X-linked muscular dystrophy. Shown is the experimental workflow
used in the proteomic analysis of 12-month old mouse kidney using an Orbitrap Fusion Tribrid mass spectrometer, as well as the bioinformatic PANTHER analysis of
the distribution of protein classes within the assessable kidney proteome.
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of 28 %, and resulting MS/MS ions were measured in the linear ion
trap. The typical MS/MS scan conditions were as follows: a targeted
AGC value of 2E+ 04 and a maximum fill time of 35ms.
2.4. Data analysis
Mass spectrometric files (.raw) were first searched qualitatively
against the UniProtKB-SwissProt Mus musculus database using Proteome
Discoverer 1.4 (Thermo Fisher) and Sequest HT (SEQUEST HT algo-
rithm, licence Thermo Scientific, registered trademark University of
Washington, USA). The following settings were used: (i) peptide mass
tolerance set to 10 ppm, (ii) MS/MS mass tolerance set to 0.02 Da, (iii) a
maximum of two missed cleavages, (iv) carbamidomethylation set as a
fixed modification (v) methionine oxidation set as a variable mod-
ification and (vi) peptide confidence set to high. Subsequently
Progenesis QI for Proteomics software (version 3.1; Non-Linear
Dynamics, a Waters company, Newcastle upon Tyne, UK) was used for
the quantitative analysis of kidney proteins from wild type versus mdx-
4cv mice. A reference run was selected and all other runs were aligned
to this run, thus allowing for any drift in retention time (Murphy et al.,
2019b). Prior to being exported as a MASCOT generic file (mgf) to
Proteome Discoverer 2.1 (Thermo Scientific) the MS/MS data files were
filtered using the following settings: (i) peptide features with
ANOVA≤ 0.01 between experimental groups, (ii) mass peaks with
charge states from +1 to +5 and (iii) greater than one isotope per
peptide. Protein identification was performed using Proteome Dis-
coverer 2.1 against Mascot (version 2.3, Matrix Science, Boston, MA,
USA) and Sequest HT using the UniProtKB-SwissProt Mus musculus
database. The following search parameters were used: (i) peptide mass
tolerance set to 10 ppm, (ii) MS/MS mass tolerance set to 0.02 Da, (iii)
Table 1
Proteomic identification of kidney proteins with an increased abundance in the mdx-4cv model of Duchenne muscular dystrophy.
Accession Gene name Description Unique peptides Confidence score Anova (p) Max fold change
P12710 Fabp1 Fatty acid-binding protein FABP1 2 7.7091 0.00015 21.89
P32848 Pvalb Parvalbumin alpha 2 6.7064 0.02782 14.41
B1AVD1 Xpnpep2 Xaa-Pro aminopeptidase 2 7 23.6486 2.32E-06 7.6
E9Q4P1 Wdfy1 WD repeat and FYVE domain-containing protein 1 2 5.9427 0.00133 7.19
P54869 Hmgcs2 Hydroxymethyl-glutaryl-CoA synthase, mitochondrial 5 14.1774 8.82E-13 5.81
O35490 Bhmt Betaine–homocysteine S-methyltransferase 1 5 17.2183 1.50E-08 5.54
Q9JIL4 Pdzk1 Na(+)/H(+) exchange regulatory cofactor NHE-RF3 3 15.5914 3.02E-09 3.74
P49429 Hpd 4-hydroxyphenyl-pyruvate dioxygenase 5 16.2034 7.00E-08 3.28
Q9QZE5 Copg1 Coatomer subunit gamma-1 2 8.01240 0.03028 3.08
Q9D7G0 Prps1 Ribose-phosphate pyrophosphokinase 1 2 7.3691 0.01469 3.03
P14246 Slc2a2 Solute carrier family 2, facilitated glucose transporter member 2 2 5.5109 0.03283 2.97
Q8CIM7 Cyp2d26 Cytochrome P450 2D26 4 12.4466 1.23E-07 2.69
P01029 C4b Complement C4-B 2 8.1508 0.03575 2.54
Q99K67 Aass Alpha-aminoadipic semialdehyde synthase, mitochondrial 2 8.3073 0.00120 2.47
Q61941 Nnt NAD(P) transhydrogenase, mitochondrial 17 58.5686 0.00017 2.44
Q64374 Rgn Regucalcin 2 6.7339 0.00064 2.43
P32067 Ssb Lupus La protein homolog 2 8.5021 0.02163 2.31
O35728 Cyp4a14 Cytochrome P450 4A14 5 17.0102 5.95E-05 2.3
P70691 Ugt1a2 UDP-glucuronosyl-transferase 1-2 6 24.0153 0.00813 2.22
P00493 Hprt1 Hypoxanthine-guanine phosphoribosyl-transferase 5 22.8354 9.56E-10 2.21
O35381 Anp32a Acidic leucine-rich nuclear phosphoprotein 32 family member A 2 6.4504 6.65E-05 2.18
P07356 Anxa2 Annexin A2 2 7.5966 0.01914 2.18
P05063 Aldoc Fructose-bisphosphate aldolase C 2 5.5440 0.00796 2.15
P0DP27 Calm2 Calmodulin-2 2 6.7473 0.00084 2.1
Q8VBW8 Ttc36 Tetratricopeptide repeat protein 36 3 11.1460 2.55E-07 2.08
Q9Z2V4 Pck1 Phosphoenolpyruvate carboxykinase, cytosolic 4 11.8760 1.65E-06 1.99
B2RX12 Abcc3 Canalicular multispecific organic anion transporter 2 2 6.8818 0.02221 1.98
Q91W43 Gldc Glycine dehydrogenase (decarboxylating), mitochondrial 5 22.2066 0.00021 1.97
A6×935 Itih4 Inter alpha-trypsin inhibitor, heavy chain 4 3 11.1462 0.00140 1.94
P62814 Atp6v1b2 V-type proton ATPase subunit B, brain isoform 4 16.0112 0.00024 1.91
Q8CFA2 Amt Aminomethyltransferase, mitochondrial 2 5.4561 7.21E-08 1.89
P11679 Krt8 Keratin, type II cytoskeletal 8 2 6.0165 0.00304 1.87
Q8VCW8 Acsf2 Acyl-CoA synthetase family member 2, mitochondrial 3 16.8266 0.00140 1.83
Q99JW2 Acy1 Aminoacylase-1 9 25.7654 1.55E-06 1.79
Q9JK42 Pdk2 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial 2 8.4047 4.11E-07 1.76
P56402 Aqp2 Aquaporin-2 2 6.6277 0.03090 1.76
P06797 Ctsl Cathepsin L1 2 9.3236 2.98E-05 1.73
P08905 Lyz2 Lysozyme C-2 3 12.0437 2.92E-06 1.71
P24549 Aldh1a1 Retinal dehydrogenase 1 5 19.2361 2.75E-06 1.69
O08691 Arg2 Arginase-2, mitochondrial 3 10.7187 0.02066 1.68
Q6A4L0 Slc22a13 Solute carrier family 22 member 13 2 7.0632 0.00970 1.64
Q9QXD6 Fbp1 Fructose-1,6-bisphosphatase 1 4 21.5767 2.12E-07 1.63
Q9D819 Ppa1 Inorganic pyrophosphatase 2 9.2567 0.00317 1.62
Q3V0K9 Pls1 Plastin-1 2 7.3772 1.21E-05 1.61
O35409 Folh1 Glutamate carboxypeptidase 2 2 10.0178 0.00328 1.58
A2ATU0 Dhtkd1 Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, mitochondrial 4 10.3485 0.00207 1.57
Q6PDN3 Mylk Myosin light chain kinase, smooth muscle 4 11.6538 0.00332 1.57
Q6AW69 Cgnl1 Cingulin-like protein 1 2 6.4156 0.00656 1.56
Q8K2I4 Manba Beta-mannosidase 4 12.0985 0.00030 1.56
Q9QXD1 Acox2 Peroxisomal acyl-coenzyme A oxidase 2 12 36.8270 4.51E-06 1.55
P58137 Acot8 Acyl-coenzyme A thioesterase 8 2 7.6040 0.00046 1.53
Q9WVT6 Ca14 Carbonic anhydrase 14 2 5.38492 1.46E-06 1.52
P62137 Ppp1ca Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 2 5.8612 0.02301 1.52
A2AKK5 Acnat1 Acyl-coenzyme A amino acid N-acyltransferase 1 5 17.7123 0.00359 1.51
Q60825 Slc34a1 Sodium-dependent phosphate transport protein 2A 5 21.4317 4.84E-05 1.5
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up to two missed cleavages, (iv) carbamidomethylation set as a fixed
modification and (v) methionine oxidation set as a variable modifica-
tion. For re-importation back into Progenesis LCeMS software as a
PepXML file only peptides with either ion scores of 40.00 or more (from
Mascot) and peptides with XCorr scores ≥ 1.5 (from Sequest HT) were
allowed. The following criteria were applied to assign proteins as po-
sitively identified: (i) an ANOVA score between experimental groups of
≤0.01, and (ii) proteins with ≥2 peptides matched. The freely avail-
able software packages PANTHER (Mi et al., 2017; http://pantherdb.
org/) and STRING (Szklarczyk et al., 2017; https://string-db.org/) were
used to identify protein classes and characterise potential protein in-
teractions, respectively.
2.5. Comparative immunoblot analysis
Immunoblotting was used as an orthogonal method for the in-
dependent verification of changes in newly identified proteins in the
kidney of the mdx-4cv mouse model of dystrophinopathy (Murphy
et al., 2019a). Individual protein samples (12.5 μg protein per lane for
Coomassie staining; and 25 μg protein per lane for immunoblotting)
were run on NuPAGE Novex Bis‐Tris Gels (Invitrogen) under standard
conditions. Protein concentration was determined using the Bradford
assay system (Bradford, 1976). For comparative analyses, Coomassie
staining of protein gels was carried out with InstantBlue Coomassie
Protein Stain (Expedeon). Proteins were transferred to nitrocellulose
membranes, blocked and incubated with primary antibody overnight,
followed by detection with peroxidase-conjugated secondary antibodies
using the enhanced chemiluminescence method. Densitometric scan-
ning and statistical analysis of immunoblots was performed using a HP
PSC-2355 scanner and ImageJ software (NIH, Bethesda, MD, USA)
along with Microsoft excel in which statistical significance was based
on a p-value ≤ 0.05.
2.6. Comparative histology and immunofluorescence microscopy
In order to establish the loss of the skeletal muscle dystrophin iso-
form Dp427-M in the mdx-4cv mouse model of dystrophinopathy and
correlate it to potential changes in the kidney, histological haematox-
ylin and eosin staining, as well as immunofluorescence microscopy
were carried out by standardized methodology. Freshly dissected
kidney and skeletal muscle specimens from 12-month old wild type and
mdx-4cv mice were quick-frozen in liquid nitrogen-cooled isopentane
and 10 μm sections cut in a cryostat. For dystrophin immuno-staining,
unfixed cryosections were boiled in phosphate-buffered saline for 5min
as previously described in detail (Murphy et al., 2019b). For FABP1 and
ACSM3 staining, sections were fixed in a 1:1 (v/v) mixture of methanol
and acetone for 10min at room temperature and then blocked with
1:20 diluted normal goat serum for 30min at room temperature. Pri-
mary antibodies were diluted appropriately in phosphate-buffered
saline for overnight incubation at 4 °C. Tissue specimens were carefully
washed and then incubated with fluorescently-labelled secondary an-
tibodies, using either 1:200 diluted anti-rabbit Alexa Fluor 488 anti-
body or 1:200 diluted anti-mouse RRX antibody for 45min at room
temperature. Nuclei were counter-stained with 1 μg/ml bis-benzimide
Hoechst 33,342. Antibody-labelled kidney and muscle tissue sections
were embedded in Fluoromount G medium and viewed under a Zeiss
Axioskop 2 epifluorescence microscope equipped with a digital Zeiss
AxioCam HRc camera (Carl Zeiss Jena GmbH, Jena, Germany).
For Sudan Black staining, fresh kidney tissue sections were fixed in
10 % formalin, washed under tap water, rinsed with distilled water and
then exposed twice for 5min to propylene glycol. Incubation with
Sudan Black B (0.7 g dye in 100ml propylene glycol) was carried out
for 7min with agitation, followed by 3min in 85 % propylene glycol,
rinsing with distilled water, washing with tap water, another rinsing
step with distilled water and finally mounting in an aqueous mounting
media of glycerin jelly.
Table 2
Proteomic identification of kidney proteins with a decreased abundance in the mdx-4cv model of Duchenne muscular dystrophy.
Accession Gene name Description Unique peptides Confidence score Anova (p) Max fold change
Q3UNX5 Acsm3 Acyl-coenzyme A synthetase ACSM3, mitochondrial 3 10.8408 0.04215 138.93
P97872 Fmo5 Dimethylaniline monooxygenase [N-oxide-forming] 5 3 10.1945 0.01630 103.18
P28665 Mug1 Murinoglobulin-1 6 28.5659 0.00010 3.52
P15392 Cyp2a4 Cytochrome P450 2A4 3 9.1835 5.67E-06 3.46
P57016 Lad1 Ladinin-1 3 10.7561 1.36E-08 2.96
P11087 Col1a1 Collagen alpha-1(I) chain 2 7.9578 1.76E-06 2.24
Q01149 Col1a2 Collagen alpha-2(I) chain 4 12.6703 1.54E-07 2.19
Q8C0I1 Agps Alkyldihydroxyacetone-phosphate synthase, peroxisomal 5 17.3564 0.00039 2.02
Q7TNG8 Ldhd D-lactate dehydrogenase, mitochondrial 3 7.2202 0.00032 1.98
Q9JI33 Ntn4 Netrin-4 2 7.6159 9.74E-08 1.93
O55029 Copb2 Coatomer subunit beta 2 7.0038 0.00228 1.91
P01872 Ighm Immunoglobulin heavy constant mu 3 8.1050 0.03329 1.91
Q9JK53 Prelp Prolargin 2 5.5677 2.66E-06 1.87
O89053 Coro1a Coronin-1A 2 7.6804 0.00034 1.83
Q02788 Col6a2 Collagen alpha-2(VI) chain 8 26.2823 1.06E-07 1.78
Q9DC50 Crot Peroxisomal carnitine O-octanoyltransferase 2 5.3420 0.02421 1.76
Q91WV7 Slc3a1 Neutral and basic amino acid transport protein rBAT 2 5.4986 0.01564 1.73
Q64FW2 Retsat All-trans-retinol 13,14-reductase 3 8.6878 1.13E-05 1.72
P47740 Aldh3a2 Fatty aldehyde dehydrogenase 3 7.5906 0.02707 1.69
P50172 Hsd11b1 Corticosteroid 11-beta-dehydrogenase isozyme 1 4 11.6482 0.00010 1.68
Q8VC12 Uroc1 Urocanate hydratase 6 20.4403 0.00169 1.67
P20918 Plg Plasminogen 2 6.05155 0.00137 1.66
Q9JJU8 Sh3bgrl SH3 domain-binding glutamic acid-rich-like protein 2 5.6793 5.00E-05 1.65
Q08857 Cd36 Platelet glycoprotein 4 2 6.1668 0.00043 1.65
P00329 Adh1 Alcohol dehydrogenase 1 2 5.1563 0.03316 1.64
P43276 Hist1h1b Histone H1.5 2 6.5163 7.05E-05 1.63
Q9WU78 Pdcd6ip Programmed cell death 6-interacting protein 2 6.4367 0.00077 1.62
Q9R0H0 Acox1 Peroxisomal acyl-coenzyme A oxidase 1 2 4.3429 0.01386 1.6
P07758 Serpina1a Alpha-1-antitrypsin 1-1 3 14.9066 1.65E-05 1.59
Q99K41 Emilin1 EMILIN-1 2 7.63098 0.00167 1.53
Q04857 Col6a1 Collagen alpha-1(VI) chain 4 10.5504 1.74E-08 1.53
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3. Results
Since X-linked muscular dystrophy is associated with renal dys-
function, it was of interest to perform a proteomic survey of the kidney
from the dystrophic mdx-4cv mouse. Prior to the mass spectrometric
analysis of kidney extracts, the dystrophic and mutant status of the
genetic mouse model of dystrophinopathy was established by histolo-
gical analysis and immunofluorescence microscopy. Fig. 1 shows
transverse cryosections from gastrocnemius muscle and confirms ab-
normal fibre diameters, central nucleation, cellular degeneration and
inflammation in mdx-4cv skeletal muscle, as well as the loss of dystro-
phin isoform Dp427-M at the fibre periphery.
3.1. Proteomic profiling of mouse kidney
A crucial prerequisite for the biochemical establishment of pro-
teome-wide changes in the kidney from the mdx-4cv model of X-linked
muscular dystrophy is the comprehensive coverage of the experimen-
tally assessable protein complement from total kidney extracts. The
proteomic analysis of 12-month old mouse kidney using an Orbitrap
Fusion Tribrid mass spectrometer, presented in this report, is based on
the mass spectrometric identification of 5878 renal protein species. The
bioinformatics PANTHER analysis of the distribution of protein classes
within the assessable kidney proteome is presented in Fig. 2, in addition
to the bioanalytical workflow used for the analysis of the mdx-4cv
kidney. Tables listing the most abundant kidney proteins identified by
proteomics, as well as kidney marker proteins with characteristic tissue
distributions and physiological functions are provided in an accom-
panying Data-in-Brief manuscript (Dowling et al., 2019). The multi-
consensus file of mouse kidney, which forms the basis of this study, is
available through the Open Science Framework under the project title
‘Proteomic profiling of mouse kidney’ (Dowling et al., 2019). The file
includes data from the analysis of 28 separate mass spectrometric
sample runs (2 technical repeats of 14 biological repeats) consisting of
high confidence peptides that were filtered based on Xcorr values. The
identified spectrum of kidney-associated proteins ranged from small
proteins (alpha-B-crystallin of 22 kDa; 9 unique peptides, 62 % se-
quence coverage) to medium-size proteins (endoplasmic reticulum
calcium ATPase SERCA2 of 115 kDa; 43 unique peptides, 46 % se-
quence coverage) to very large proteins (cytoplasmic dynein heavy
chain of 532 kDa; 184 unique peptides, 50 % sequence coverage).
A wide range of kidney-associated proteins, as previously
Fig. 3. Label-free quantitative proteomic analysis of wild-type versus mdx-4cv kidney. Depicted is the result from hierarchical clustering of the mean protein
expression values of statistically significant differentially abundant proteins.
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established by antibody-based methodology (Habuka et al., 2014), were
identified with solid sequence coverage including renal marker proteins
belonging to the glomeruli (podocin; 4 unique peptides, 18 % sequence
coverage), the proximal tubule cytoplasm (inositol oxygenase; 12 un-
ique peptides, 74 % sequence coverage), the proximal tubule baso-
lateral membrane (solute carrier SLC22A2; 5 unique peptides, 10 %
sequence coverage), the proximal tubule luminal membrane (solute
carrier SLC22A12; 12 unique peptides, 19 % sequence coverage), the
distal tubule luminal membrane (ATP-sensitive inward rectifier po-
tassium channel KCNJ1; 3 unique peptides, 10 % sequence coverage)
and the collecting duct luminal membrane (aquaporin AQP2; 3 unique
peptides, 13 % sequence coverage). A highly specific kidney marker
protein is uromodulin, which is exclusively produced by epithelial cells
in the thick ascending limb cells of the kidney, where it regulates ion
transport, as well as protects via immunomodulation against urinary
tract infection and kidney stones (Garimella and Sarnak, 2017). Ur-
omodulin (Q91 X17; Umod gene product), was identified by 18 unique
peptides and a 33 % sequence coverage in all analysed 28 kidney
samples. Another type of highly kidney-enriched proteins is the diverse
family of solute carriers that regulate specific aspects of renal trans-
membrane transport in the proximal and distal tubule system and the
collecting ducts (Momper and Nigam, 2018). The kidney-enriched so-
lute carriers SLC12A1 (SLC family 12, member 1; 33 unique peptides;
40 % sequence coverage) and SLC22A8 (SLC family 22, member 8; 10
unique peptides, 20 % sequence coverage) were clearly identified in
this study, together with 38 other isoforms of this protein family of
solute carriers (Habuka et al., 2014).
Key regulators involved in kidney physiology are represented by the
Na+/Ca2+-exchanger, the Na+/glucose-cotransporter and the plasma-
lemmal membrane Ca2+-ATPase, as well as the highly abundant renal
Na+/K+-ATPase (Xie et al., 2013). Various isoforms of these kidney
marker proteins were covered by the proteomic profiling presented in
this study, including the Na+/Ca2+-exchangers NCX1 (5 unique pep-
tides; 6 % sequence coverage) and NCX2 (2 unique peptides; 4 % se-
quence coverage), the Na+/glucose-cotransporters SGLT1 (13 unique
peptides; 22 % sequence coverage), SGLT2 (10 unique peptides; 16 %
sequence coverage), SGLT4 (8 unique peptides; 18 % sequence cov-
erage) and SGLT5 (8 unique peptides; 20 % sequence coverage), the
plasma membrane Ca2+-transporting ATPases ATP2B1 (27 unique
peptides; 30 % sequence coverage) and ATP2B4 (22 unique peptides;
25 % sequence coverage) and the Na+/K+-ATPase subunits alpha-1
(ATP1A1; 47 unique peptides; 50 % sequence coverage), alpha-2
(ATP1A2; 17 unique peptides; 21 % sequence coverage), alpha-3
(ATP1A3; 17 unique peptides; 24 % sequence coverage), beta-1
(ATP1B1; 15 unique peptides; 52 % sequence coverage) and beta-3
(ATP1B3; 4 unique peptides; 19 % sequence coverage). These findings
demonstrate an excellent coverage of the assessable proteome from
kidney homogenates (Arthur et al., 2018; Cañadas-Garre et al., 2019;
Klein and Schanstra, 2018).
Fig. 4. Overview of potential protein-protein interaction patterns of increased protein species in the kidney from the mdx-4cv mouse model of dystrophinopathy, as
determined by the bioinformatics software programme STRING.
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3.2. Comparative proteomic profiling of the mdx-4cv kidney
The comparative mass spectrometric analysis of wild type versus the
mdx-4cv mouse model of Duchenne muscular dystrophy resulted in the
identification of 82 decreased versus 142 increased kidney proteins.
The mass spectrometric identification of individual proteins with a
changed concentration above 1.5 fold is listed in Table 1 for increased
protein species and in Table 2 for decreased protein species, respec-
tively. Tables listing identified kidney proteins with concentration
changes below 1.5 fold are provided in an accompanying Data-in-Brief
manuscript (Dowling et al., 2019). A summarizing heat map for dif-
ferentially abundant kidney proteins is shown in Fig. 3. The most in-
creased versus decreased protein species are the FABP1 isoform of fatty
acid binding protein versus the ACSM3 isoform of mitochondrial acyl-
coenzyme A synthetase, respectively. The list of elevated kidney com-
ponents contains crucial proteins involved in Ca2+-homeostasis (par-
valbumin, regucalcin, annexin, calmodulin), and kidney metabolism,
including various mitochondrial enzymes (hydroxymethyl-glutaryl-CoA
synthase, alpha-aminoadipic semialdehyde synthase, NAD(P) transhy-
drogenase, glycine dehydrogenase, aminomethyltransferase, acyl-CoA
synthetase, pyruvate dehydrogenase kinase, arginase and 2-ox-
oglutarate dehydrogenase).
The STRING analysis shown in Fig. 4 illustrates the potential in-
teraction patterns of proteins with an increased abundance in the mdx-
4cv kidney. Highlighted is the parvalbumin complex, the large con-
stellation of metabolic enzymes, the peroxisome proliferation-activated
receptor pathway and coupling to FABP1. A striking cluster of de-
creased proteins is related to the extracellular matrix and focal adhesion
complex, as outlined in the STRING analysis of Fig. 5. Significantly
reduced proteins in the mdx-4cv kidney include the alpha-1(I), alpha-
2(I) chain, alpha-1(VI) and alpha-2(VI) chains of collagen, as well as the
leucine-rich repeat protein prolargin and the basement membrane
components ladinin and netrin. The main proteomic findings were
confirmed by immunofluorescence microscopy and comparative
Fig. 5. Overview of potential protein-protein interaction patterns of decreased protein species in the kidney from the mdx-4cv mouse model of dystrophinopathy, as
determined by the bioinformatics software programme STRING.
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immunoblotting, as outlined below.
3.3. Elevated FABP1 levels and ectopic fat depositions in the mdx-4cv
kidney
Of the 10 known FABP isoforms (Smathers and Petersen, 2011), 4
variants were identified in this study. FABP1 (L-FABP), FABP3 (H-
FABP), FABP4 (A-FABP) and FABP5 (E-FABP) were identified by 5, 7, 8
and 9 unique peptides, respectively. Comparative proteomics indicates
that the kidney-associated FABP1 isoform exhibits an approximately
20-fold increased concentration in the dystrophic phenotype (Table 1).
Immunoblot analysis was used to verify this finding. As shown in the
protein gel of Fig. 6, the overall protein band pattern is relatively
comparable between wild type and mdx-4cv kidneys. However, im-
munoblotting clearly revealed that FABP1 is significantly increased in
mdx-4cv kidney preparations, as compared to reduced levels of ACSM3
and unchanged levels of the glyceraldehyde-3-phosphate dehy-
drogenase protein product of the house keeping gene GAPDH. The
elevated concentration of FABP1, as determined by proteomics and
confirmed by immunoblotting, was correlated to cell biological changes
using histological and immunofluorescence microscopical metho-
dology. The basic histological structure of glomerulus and convoluted
tubules was stained by haematoxylin and eosin (Fig. 7). The comparison
of kidney sections from wild type versus mdx-4cv mice showed in-
creased levels of diffuse whitish deposits in the mdx-4cv kidney. Im-
portantly, an increased intensity of Sudan Black labelling of kidney cells
revealed ectopic fat deposition. Antibody labelling of FABP1 confirmed
increased levels of this fatty acid binding protein in the mdx-4cv kidney,
as well as a decreased concentration of the ACSM3 isoform of mi-
tochondrial acyl-coenzyme A synthetase (Fig. 7).
4. Discussion
The identification and characterization of novel biomarker candi-
dates is crucial for the improved diagnosis, prognosis and therapy-
monitoring in the field of muscular dystrophy (Hathout et al., 2016;
Carr et al., 2018; Spitali et al., 2018), giving mass spectrometry-based
proteomics a central place in the systems biological study of dystro-
phinopathy (Burch et al., 2015; Dowling et al., 2019). The compre-
hensive biochemical analysis of proteome-wide changes in the mdx-4cv
mouse promises to identify novel biomarker candidates, which may be
useful for future evaluations of new experimental therapies. The de-
vastating effects of muscular dystrophy are complicated by physiolo-
gical and biochemical disturbances of whole body homeostasis and the
fact that the tissue-specific expression of dystrophin isoforms is driven
by seven promoters that independently produce Dp427-B in the brain,
Dp427-M contractile tissues, Dp427-P in Purkinje cells, Dp260-R in the
retina, Dp140-B/K in brain and kidney, Dp116-S in Schwann cells und
the ubiquitous Dp71-G in the brain and various other tissues (Muntoni
et al., 2003). Thus, genetic rearrangements in the 79 exon-spanning
DMD gene have complex effects on the expression of the various dys-
trophin isoforms in individual cases of muscular dystrophy. Here, we
could show that the mdx-4cv animal model of dystrophinopathy ex-
hibits considerable changes in the kidney proteome. In analogy to
previous findings from the systematic proteomic analysis of this dys-
trophic mouse model on fibre degeneration and reactive myofibrosis
(Holland et al., 2015; Murphy et al., 2018a, 2019a, 2019b), this report
confirms the multi-system pathology due to deficiency in dystrophin.
Kidney proteomics and kidney disease biomarker research has
greatly intensified over the last few years, as outlined in several ex-
tensive reviews (Fenton, 2018; Rysz et al., 2017; Zhang and Parikh,
Fig. 6. Immunoblot analysis of fatty acid binding protein FABP1 and the ACSM3 isoform of mitochondrial acyl-coenzyme A synthetase in kidney preparations from
wild type versus dystrophic mice. Shown is a protein gel of wild type (wt) versus mdx-4cv kidney extracts, and immunoblots of two separate preparations labelled
with antibodies to FABP1, ACSM3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The statistical evaluation of antibody labelling is shown to the right
and below the immunoblotting images (FABP1: p= 1.173E-05, n=7; ACSM3: p= 0.0779, n=7; GAPDH: p=0.747, n= 7).
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Fig. 7. Histological and immunofluorescence microscopical analysis of the mdx-4cv kidney. Shown are transverse sections of wild type (wt) versus mdx-4cv kidney
stained with haematoxylin and eosin (H&E) or Sudan Black, as well as immuno-labelled with antibodies to fatty acid binding protein FABP1 or the ACSM3 isoform of
mitochondrial acyl-coenzyme A synthetase. Bar equals 50 μm.
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2019). The international effort to characterize the kidney proteome and
the initiation of the Kidney and Urine Proteome Project (HKUPP) has
led to the identification and cataloguing of several thousand kidney-
associated protein species and dynamic proteo-forms in health and
disease (Arthur et al., 2018; Cañadas-Garre et al., 2019; Klein and
Schanstra, 2018). Transcriptomics in combination with antibody-based
profiling of the human kidney has led to the establishment of the renal-
specific protein complement including the identification of protein
markers of distinct cellular structures, such as the glomeruli, proximal
tubules, distal tubules and collecting ducts (Habuka et al., 2014).
Building on these extensive proteomic maps of the kidney, this report
has employed an Orbitrap Fusion Tribrid mass spectrometer for the
comparative profiling of kidney preparations.
Proteome-wide changes appear to affect especially mitochondrial
metabolism, the regulation of Ca2+-homeostasis and the integrity of the
extracellular matrix and focal adhesion complex in the mdx-4cv kidney.
This makes the ACSM3 isoform of mitochondrial acyl-coenzyme A
synthetase, as well as collagen COL-I, collagen COL-VI, prolargin and
related basement membrane proteins, new biomarker candidates of
renal changes in the mdx-4cv animal model. One of the most interesting
pathobiochemical findings from the systematic proteomic analysis of
the mdx-4cv kidney is the significant increase in the FABP1 isoform of
fatty acid binding protein. FABP1 belongs to the protein family of in-
tracellular lipid-binding proteins, which act as mediators of reversible
binding of hydrophobic ligands and their subsequent trafficking
through major subcellular systems (Thumser et al., 2014). The estab-
lished FABP isoforms 1–9 have been named after their original dis-
covery and abundance in particular tissues, such as L-FABP (liver), I-
FABP (intestine), H-FABP (heart), A-FABP (adipocytes), E-FABP (epi-
dermal tissue), Il-FABP (ileum), B-FABP (brain), M-FABP (myelin) and
T-FABP (testis). The mass spectrometrically identified isoform FABP1 is
also known as heme-binding protein, Z protein or hepatic FABP, and
has been located in liver, kidney, intestine, pancreas, lung and stomach
(Smathers and Petersen, 2011). Although the proteomic results and cell
biological findings presented in this report do not demonstrate a direct
functional link between increased FABP1 and fat accumulation, the
findings indicate that the up-regulation of FABP1 may be related to
abnormal fat metabolism. The elevated concentration of FABP1 might
occur in association with ectopic fat deposition in the affected kidney,
and this may play a pathophysiological role in renal dysfunction (Xu
et al., 2015). The accumulation of ectopic fat might trigger impaired
kidney performance, which may progress to the cardio-renal syndrome
in dystrophinopathy (Villa et al., 2016).
Proteomic changes in fatty acid binding proteins suggest alterations
in the binding of long-chain fatty acids and other lipophilic ligands
(Thumser et al., 2014). Since fatty acid binding proteins also act as
myokines and adipokines and function as regulators of metabolic sig-
nalling events, their altered concentration may be related to changes in
metabolic control and associated cellular mechanisms (Hotamisligil and
Bernlohr, 2015). The increased presence of FABP1 in the mdx-4cv
kidney is reflected by its identification, together with FABP3 and
FABP5, in the albumin-depleted serum from the mdx-4cv mouse
(Murphy et al., 2017). Interestingly, FABP1 has recently been suggested
as a general marker of chronic kidney damage (Lipiec et al., 2018). In
addition, the increase of FABP1 in the mdx-4cv kidney is mirrored by a
drastic up-regulation of FABP5 in the mdx-4cv liver, as determined by a
proteomic survey of hepatic tissue (Murphy et al., 2018b). Thus, al-
terations in FABP1 and FABP5 can be useful as general pathobiochmical
markers of secondary changes in kidney and liver tissue, respectively, in
the mdx-4cv mouse model of dystrophinopathy.
In conclusion, the proteomic survey of the mdx-4cv kidney has
shown a considerable increase in FABP1, which is probably related to
abnormal fat deposits and disturbed fat metabolism. This makes this
particular isoform of fatty acid binding protein an interesting new
biomarker candidate for the evaluation of renal dysfunction in animal
models of X-linked muscular dystrophy.
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